Albshesh, A., Ungar, B., Horin, S.Ben., et al. (2020) Terminal Ileum Thickness during Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease. Inflammatory Bowel Diseases, 26, 1619-1625.
https://doi.org/10.1093/ibd/izaa219

has been cited by the following article:

• TITLE: Progress of Transmural Healing in Crohn’s Disease

  AUTHORS: Yinan Han, Xiaoping Tan

  KEYWORDS: Transmural Healing, Inflammatory Bowel Disease, Crohn’s Disease

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.5, May 28, 2024

  ABSTRACT: Recently transmural healing (TH) has become a subject of increasing interest as a potential therapeutic purpose for inflammatory bowel disease (IBD). Crohn’s disease (CD) is characterized by chronic inflammation of the gastrointestinal tract, which can involve any part of the digestive tract, and the lesions are usually discontinuous, with progressive and destructive transmural lesions that can lead to irreversible damage such as fibrotic strictures, complications such as fistulas and abscesses. Disease remission remains the primary goal of therapeutic management; however transmural healing is a very promising endpoint for monitoring treatment response. Along with small bowel imaging tests such as computed tomography scans Intestinal imaging (CTE), magnetic resonance intestinal imaging (MRE), intestinal ultrasound (IUS) and other related imaging technologies are popularized in CD diagnosis and treatment benefit. Transmural healing has been initially used in clinical practice and the correlation between its rules and long-term clinical remission has been explored.